@article{eabf11c537ba46ff9b25ad5dc95b1fbe,
title = "Skeletal Muscle Weakness: A Novel Treatable Trait in Asthma?",
author = "Hannu Kankaanranta and Pinja Ilmarinen",
note = "Funding Information: H. Kankaanranta is an asthma and allergy research professor funded by the Hermann Krefting Foundation and his work is supported by Swedish Heart and Lung Foundation, Swedish Asthma & Allergy Foundation , ALF agreement (ALFGBG-966075; grant from the Swedish state under the agreement between the Swedish Government and the county councils), Swedish Research Council (2022-01022), Tampere Tuberculosis Foundation (Tampere, Finland), the Finnish Anti-Tuberculosis Association Foundation, and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland). Funding Information: H. Kankaanranta is an asthma and allergy research professor funded by the Hermann Krefting Foundation and his work is supported by Swedish Heart and Lung Foundation, Swedish Asthma & Allergy Foundation, ALF agreement (ALFGBG-966075; grant from the Swedish state under the agreement between the Swedish Government and the county councils), Swedish Research Council (2022-01022), Tampere Tuberculosis Foundation (Tampere, Finland), the Finnish Anti-Tuberculosis Association Foundation, and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland).Conflicts of interest: H. Kankaanranta reports personal fees for lectures and consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharma, GSK, MSD, Novartis, Orion Pharma, and Sanofi Genzyme, outside the submitted work. P. Ilmarinen is employed by GSK Finland as a scientific advisor.",
year = "2023",
month = may,
doi = "10.1016/j.jaip.2023.02.015",
language = "English",
volume = "11",
pages = "1448--1449",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "5",
}